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Abstract
Background: The high prevalence of methicillin-resistant S. aureus (MRSA) has led clinicians to select antibiotics
that have coverage against MRSA, usually vancomycin, for empiric therapy for suspected staphylococcal infections.
Clinicians often continue vancomycin started empirically even when methicillin-susceptible S. aureus (MSSA) strains
are identified by culture. However, vancomycin has been associated with poor outcomes such as nephrotoxicity,
persistent bacteremia and treatment failure. The objective of this study was to compare the effectiveness of
vancomycin versus the beta-lactam antibiotics nafcillin and cefazolin among patients with MSSA bacteremia. The
outcome of interest for this study was 30-day in-hospital mortality.
Methods: This retrospective cohort study included all adult in-patients admitted to a tertiary-care facility between
January 1, 2003 and June 30, 2007 who had a positive blood culture for MSSA and received nafcillin, cefazolin or
vancomycin. Cox proportional hazard models were used to assess independent mortality hazards comparing nafcillin or
cefazolin versus vancomycin. Similar methods were used to estimate the survival benefits of switching from
vancomycin to nafcillin or cefazolin versus leaving patients on vancomycin. Each model included statistical adjustment
using propensity scores which contained variables associated with an increased propensity to receive vancomycin.
Results: 267 patients were included; 14% (38/267) received nafcillin or cefazolin, 51% (135/267) received both
vancomycin and either nafcillin or cefazolin, and 35% (94/267) received vancomycin. Thirty (11%) died within 30 days.
Those receiving nafcillin or cefazolin had 79% lower mortality hazards compared with those who received
vancomycin alone (adjusted hazard ratio (HR): 0.21; 95% confidence interval (CI): 0.09, 0.47). Among the 122 patients
who initially received vancomycin empirically, those who were switched to nafcillin or cefazolin (66/122) had 69%
lower mortality hazards (adjusted HR: 0.31; 95% CI: 0.10, 0.95) compared to those who remained on vancomycin.
Conclusions: Receipt of nafcillin or cefazolin was protective against mortality compared to vancomycin even when
therapy was altered after culture results identified MSSA. Convenience of vancomycin dosing may not outweigh
the potential benefits of nafcillin or cefazolin in the treatment of MSSA bacteremia.
Background
Through the American Recovery and Reinvestment Act
of 2009, Congress requested that the Institute of Medi-
cine (IOM) recommend national priorities for research
questions to be addressed by Comparative Effectiveness
Research. The first quartile of the IOM’s list included a
call to compare the effectiveness of strategies for redu-
cing healthcare-associated infections [1]. One such strat-
e g yt or e d u c ea n t i b i o t i cr e s i s tant healthcare-associated
infections would be to optimize antibiotic therapy.
The high prevalence of methicillin-resistant Staphylo-
coccus aureus (MRSA) has led clinicians to select anti-
biotics that have coverage against MRSA, usually
vancomycin, for empiric therapy for suspected staphylo-
coccal infections [2,3] Patients treated initially with
empiric vancomycin are frequently continued on
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results identify methicillin-susceptible S. aureus (MSSA),
particularly in patients with renal insufficiency [4]. How-
ever, high vancomycin selective pressure may lead to
decreased susceptibility to vancomycin in both MSSA
and MRSA [5].
Vancomycin has been associated with poor outcomes
such as nephrotoxicity, persistent bacteremia and treat-
ment failure among MSSA patients [3,5-9]. Higher mor-
tality in patients with MRSA bacteremia compared to
patients with MSSA bacteremia has been attributable to
differences in host viability, differences in microbial
pathogenicity, and differences in antimicrobial potency,
particularly the inferior anti-staphylococcal killing of gly-
copeptides when compared to the beta-lactam antibiotics
nafcillin or cefazolin [7,8,10,11].
Comparative effectiveness research methods are an ideal
methodology to compare treatments for S. aureus infec-
tions because these methods aim to determine effective-
ness in the real-world setting. This study aimed to assess
differences in 30-day in-hospital mortality in patients with
MSSA bacteremia treated with nafcillin or cefazolin com-
pared to those treated with vancomycin. Additionally, we
assessed whether those treated empirically with vancomy-
cin would benefit if switched to nafcillin or cefazolin once
MSSA was microbiologically identified.
Methods
Study design and patient population
This retrospective cohort study included adult patients
admitted to the University of Maryland Medical Center, a
656-bed tertiary care facility, between January 1, 2003 and
June 30, 2007. Patients were included in the study if they
had a positive blood culture for MSSA and received van-
comycin, nafcillin or cefazolin. Patients with polymicrobial
infections were excluded in order to only assess the anti-
biotics and outcomes associated with S. aureus infection.
Patients who only received antibiotics other than vanco-
mycin, nafcillin, or cefazolin were excluded from the
study. However, if a patient received vancomycin, nafcillin
or cefazolin and another antibiotic (e.g. vancomycin and
piperacillin/tazobactam) they were included in the
analysis.
Each admission was handled as an independent event
and therefore patients could be included in the study
more than once. Eligible patients were identified using a
relational database that contains medical, pharmaceutical
and microbiologic data. These data have been validated in
previous studies and have positive and negative predictive
values in excess of 99 percent when compared to paper
medical records [12,13]. Additional variables (e.g. compo-
nents of the modified Acute Physiology Score [APS]) that
were not available in the relational database were collected
by a research nurse via chart review. This study was
approved by the institutional review board of the Univer-
sity of Maryland, Baltimore.
Variable definitions
The primary outcome of interest was 30-day in-hospital
mortality, which was defined as mortality occurring dur-
ing the index hospital admission in the time period
from culture collection to 30 days after culture collec-
tion. The outcome was censored if the patient survived
longer than 30 days after culture collection or if the
patient was discharged alive within 30 days after culture
collection.
Severity of illness was measured 24 hours before the
time the culture was obtained using the modified APS. If
the blood culture was obtained within 24 hours of hospital
admission, APS at the time of admission was calculated.
The modified APS is based on the Acute Physiology and
Chronic Health Evaluation (APACHE) III score [14-16].
Since the APACHE III was designed for use among inten-
sive care unit (ICU) patients, the score has been modified
by excluding variables that are not applicable to this study
population [12-17]. The modified APS includes age,
chronic health (AIDS, hepatic failure, lymphoma, meta-
static cancer, leukemia/multiple myeloma, immunosupres-
sion, cirrhosis), and acute physiologic abnormalities
including pulse rate, mean blood pressure, temperature,
respiratory rate, hematocrit, white blood cell count, creati-
nine, pH, blood urea nitrogen, sodium, albumin, bilirubin,
and glucose [12-17]. The Charlson Comorbidity Index, an
aggregate comorbidity score, was calculated using dis-
charge International Classification of Diseases, 9
th Revi-
sion, Clinical Modification (ICD-9-CM)c o d e sf o r
comorbid conditions [18]. Blood cultures collected within
48 hours of admission were designated as community-
associated infections. Time to receipt of nafcillin or cefa-
zolin was measured from the time the blood culture was
collected to the time the patient first received nafcillin or
cefazolin. Similarly, time to receipt of appropriate therapy
was measured from the time the blood culture was col-
lected to the time the patient first received an antibiotic in
which the S. aureus isolate from the blood culture was
susceptible in vitro [19].
Antimicrobial susceptibility profiles were determined
according to Clinical and Laboratory Standards Institute
guidelines [20]. Endocarditis was defined as presence of
an ICD-9-CM code for endocarditis or echocardio-
graphic findings of vegetation on the index admission.
Hemodialysis was defined as presence of an ICD-9-CM
code for hemodialysis or chronic renal disease on the
index admission. Pneumonia and osteomyelitis were
defined by ICD-9-CM codes on the index admission.
Patients with a positive wound culture before the first
positive blood culture were classified as having a wound
infection.
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Bivariate associations were assessed using the chi-square
test or Fisher’s exact test for categorical variables and the
Students t-test or the Wilcoxon Rank Sum test for contin-
uous variables. Logistic regression models were used to
create two different propensity scores. First, a propensity
score was created using variables that were independently
associated with receipt of nafcillin or cefazolin versus van-
comycin. A separate second propensity score was created
using variables that were independently associated with
switching from vancomycin to nafcillin or cefazolin versus
remaining on vancomycin for use in the model assessing
the clinical benefits of switching to nafcillin or cefazolin if
started on vancomycin.
Cox proportional hazard models were then fit to mea-
sure hazard ratios (HRs) and 95% confidence intervals
(CIs) for the associations of interest. The first Cox propor-
tional hazard model assessed the association between
receipt of nafcillin or cefazolin versus vancomycin and
mortality controlling for the first propensity score. The
second Cox proportional hazard model assessed the asso-
ciation between switching from vancomycin to nafcillin or
cefazolin versus remaining on vancomycin and mortality
controlling for the second propensity score. All analyses
were performed using SAS software (SAS Institute, Cary,
NC) version 9.1.
Results
Overall, 326 patients had MSSA bacteremia during the
study period. Thirty-one patients were excluded from the
analysis because they did not receive nafcillin, cefazolin
or vancomycin on the index admission. Of the 31
excluded patients, 14 (45%) did not receive anti-staphylo-
coccal antibiotic therapy and 17 (55%) did not receive
vancomycin, nafcillin or cefazolin but received other
anti-staphylococcal antibiotics. Twenty-eight patients
with polymicrobial infections were excluded. A total of
267 hospital admissions from 252 individual patients
were included in the final analysis. Fourteen percent (38/
267) received nafcillin or cefazolin alone, 51% (135/267)
received both vancomycin and either nafcillin or cefazo-
lin and 35% (94/267) received vancomycin alone. Thirty
(11%) patients died within 30 days of culture collection.
All patients in this cohort received vancomycin, nafcil-
lin, or cefazolin. These patients also could have received
other antibiotics. During the index admission, 40% of the
cohort received piperacillin/tazobactam, 20% received a
third-generation cephalosporin, 12% received trimetho-
prim/sulfamethoxazole, 12% received ampicillin/sulbac-
tam, 10% received clindamycin, 9% received cefepime, 7%
received imipenem, 6% received linezolid, 2% received
daptomycin, and 2% received a second-generation cepha-
losporin. Patients who received nafcillin or cefazolin but
not vancomycin were significantly less likely to receive
other anti-staphylococcal antibiotics compared to
patients who received vancomycin (p < 0.01).
Nine percent of patients had a transthoracic echocar-
diogram (TTE) then a transesophageal echocardiography
(TEE) performed, 30% had only a TTE and 5% had only
a TEE performed. Of the 40 patients classified as having
endocarditis, 60% were classified by echocardiographic
findings of vegetation and 40% were classified via an
ICD-9-CM code for endocarditis.
Table 1 displays the association between patient and
treatment factors and receipt of antibiotics. Patients who
received nafcillin or cefazolin were less likely to have
renal disease and less likely to undergo hemodialysis,
were less likely to have a central venous catheter, and
had lower median severity of illness and comorbidity
scores compared to patients who received vancomycin
(p < 0.05). Patients who received nafcillin or cefazolin
were more likely to have endocarditis (p < 0.01). Patients
who received nafcillin or cefazolin were not significantly
different than those who received vancomycin in regards
to diagnosis of pneumonia, osteomyelitis, or wound
infections. Patients receiving nafcillin or cefazolin were
somewhat less likely to have their central venous catheter
removed (p = 0.08). However, removal of a central
venous catheter was not associated with mortality (p =
0.83) and it was not a confounder in the association
between receipt of cefazolin or nafcillin and mortality.
When 30-day in-hospital mortality was stratified by anti-
biotics received during the index admission, we found
cumulative mortality incidences of 3% (1/38) among
patients who received only nafcillin or cefazolin, 7% (10/
135) among patients who received both vancomycin and
nafcillin or vancomycin and cefazolin, and 20% (19/94)
among patients who only received vancomycin (chi-square
test for trend p < 0.01). When we excluded patients who
received both vancomycin and nafcillin or vancomycin
and cefazolin, those who received nafcillin or cefazolin
only were less likely to die compared to those who
received vancomycin only (unadjusted HR: 0.10; 95% CI:
0.01, 0.76). Those who received nafcillin or cefazolin,
including those who received both vancomycin and nafcil-
lin or cefazolin, were significantly less likely to die com-
pared to patients who received only vancomycin, after
statistically adjusting for the propensity score which
included severity of illness, aggregate comorbidity, age,
admission to the ICU prior to culture collection, hemodia-
lysis, endocarditis, time to receipt of appropriate therapy,
and receipt of other anti-staphylococcal antibiotics
(adjusted HR: 0.21; 95% CI: 0.09, 0.47) (Table 2).
In order to evaluate the benefit of switching therapy
from vancomycin to nafcillin or cefazolin, we examined
the cohort of patients who received vancomycin empiri-
cally, excluding the 13 patients who received nafcillin or
cefazolin before receipt of vancomycin. Of the 122 patients
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cin to nafcillin or cefazolin. The median time from receipt
of vancomycin to the switch to nafcillin or cefazolin was
3.0 days (interquartile range: 2.4, 3.9 days).
Patients who switched from vancomycin to nafcillin or
cefazolin were less likely to die compared to those who
remained on vancomycin (unadjusted HR: 0.33; 95% CI:
0.13, 0.87). This association remained significant after
statistically adjusting for the propensity score which
included severity of illness, aggregate comorbidity, admis-
sion to the ICU prior to culture collection, community-
associated infection, time to receipt of appropriate
Table 1 Characteristics of the study population stratified by receipt of nafcillin or cefazolin
Received only nafcillin or
cefazolin
(n = 38)
Received both nafcillin or cefazolin and
vancomycin
(n = 135)
Received only
vancomycin
(n = 94)
p
Diabetes 5 (13.2%) 7 (5.2%) 13 (14.0%) 0.06
Renal disease 0 (0%) 9 (6.7%) 13 (14.0%) 0.02
Severity of illness score, median,
IQR
11.5 (6.0, 16.0) 16.0 (7.0, 25.0) 21.0 (14.0, 29.0) <
0.01
Charlson Comorbidity Index,
median, IQR
0 (0, 2) 1 (0, 3) 2 (1,4) <
0.01
Endocarditis 9 (23.7%) 28 (20.7%) 3 (3.2%) <
0.01
Pneumonia 1 (2.6%) 12 (8.9%) 3 (3.2%) 0.13
Osteomyelitis 1 (2.6%) 7 (5.2) 1 (1.1%) 0.22
Wound Infection 3 (7.9%) 4 (3.0%) 2 (2.1%) 0.23
Hemodialysis 0 (0%) 13 (9.6%) 18 (19.2%) <
0.01
Community-associated infection 26 (68.4%) 94 (69.6%) 54 (57.5%) 0.14
ICU admission before culture
collection
6 (15.8%) 40 (29.6%) 28 (29.8%) 0.20
Age, mean ± SD, year 51.0 ± 16.4 48.0 ± 15.6 49.8 ± 16.9 0.78
Female sex 17 (44.7%) 48 (35.6%) 32 (34.0%) 0.49
Presence of central venous
catheter
19 (50.0%) 61 (45.2%) 59 (62.8%) 0.03
Central venous catheter removed 8/19 (42.1%) 43/61 (70.5%) 38/59 (64.4%) 0.08
Data are no. (%) of admissions, unless otherwise indicated. IQR, interquartile range; ICU, intensive care unit; SD, standard deviation.
Table 2 Propensity score adjusted associations between receipt of nafcillin or cefazolin versus vancomycin and 30-day
in-hospital mortality
Association Adjusted hazard ratio and 95%
confidence interval
Variables included in the
propensity score
Receipt of nafcillin or cefazolin versus vancomycin and 30-day in-hospital
mortality
0.21 (0.09, 0.47) Severity of illness
Aggregate comorbidity
Admission to the ICU
Age
Hemodialysis
Endocarditis
Time to receipt of
appropriate therapy
Receipt of other anti
-staphylococcal antibiotic
Switch from vancomycin to nafcillin or cefazolin versus remaining on
vancomycin and 30-day in-hospital mortality
0.31 (0.10, 0.95) Severity of illness
Aggregate comorbidity
Admission to the ICU
Community-associated
infection
Hemodialysis
Age
Endocarditis
Time to receipt of
appropriate therapy
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HR: 0.31; 95% CI: 0.10, 0.95) (Table 2). The association
remained when the six patients who died or were dis-
charged within 24 hours of culture collection were
excluded. Similarly, switching from vancomycin to nafcil-
lin or cefazolin remained protective when this variable
was treated as a time varying covariate in the statistical
analysis.
Among the subset of 139 patients who had a central
venous catheter, receipt of nafcillin or cefazolin was pro-
tective against mortality after statistically adjusting for
the propensity score (adjusted HR: 0.26; 95% CI: 0.10,
0.69). When the cohort was stratified by severity of illness
(modified APS≤16 or > 16), the cumulative mortality
incidences in both strata were lowest among patients
who received nafcillin or cefazolin only (0% and 11.1%
respectively), followed by patients who received both van-
comycin and nafcillin or cefazolin (1.4% and 13.9%
r e s p e c t i v e l y )a n dh i g h e s ta mong patients who received
vancomycin only (8.6% and 27.1% respectively).
When only the first admission per patient was ana-
lyzed, the results did not change. Receipt of nafcillin and
cefazolin at anytime (adjusted HR: 0.20; 95% CI: 0.09,
0.44) and switching from vancomycin to nafcillin or cefa-
zolin (adjusted HR: 0.28; 95% CI: 0.09, 0.86) remained
protective against mortality.
When analyzed separately, both nafcillin and cefazolin
were protective against mortality. These associations
remained after adjusting for propensity scores, although
the association between nafcillin and mortality was not
statistically significant (nafcillin adjusted HR: 0.45; 95%
CI: 0.18, 1.15; cefazolin adjusted HR: 0.25; 95% CI: 0.09,
0.66). Additionally, among the 173 patients who ever
received nafcillin or cefazolin, 6% died within 30 days of
culture collection. Patients who died had a longer time
to receipt of nafcillin or cefazolin (mean = 4.0 days,
standard deviation [SD] = 4.5 days) compared to those
who survived (mean = 2.5 days, SD = 6.6 days).
Discussion
Clinicians are often faced with therapeutic trade-offs that
balance risk and benefit. When faced with treating staphy-
lococcal infections, this may include balancing the ease of
administration of vancomycin compared to the more chal-
lenging administration of beta-lactam antibiotics such as
nafcillin with a potential trade-off in efficacy. In this com-
parative effectiveness analysis, we found that receipt of
nafcillin or cefazolin in MSSA bacteremic patients was
independently associated with a 79% lower adjusted rate
of mortality compared to vancomycin. In addition, switch-
ing antimicrobial therapy from vancomycin to nafcillin or
cefazolin was also highly protective against mortality.
Thus, while the initiation of empiric vancomycin therapy
in cases of suspected S. aureus bacteremia is reasonable
pending microbiological confirmation of S. aureus and
susceptibilities, this data provides strong evidence for the
importance of switching therapy to nafcillin or cefazolin
once culture results confirm MSSA bacteremia. The bene-
fit was present in this cohort even though the median time
to switching was three days, suggesting that it is beneficial
to switch away from vancomycin even in settings without
access to rapid diagnostics.
T h i ss t u d yf o u n dt h a tt h ep r o b a b i l i t yo fs u r v i v a lw a s
greater among patients who received only nafcillin or
cefazolin compared to those who received both vancomy-
cin and nafcillin or cefazolin. It could be postulated that
clinicians may prescribe more antibiotics to the patients
with severe underlying conditions, which could lead to
these results. However, this trend remained even after
the cohort was stratified by severity of illness. Another
potential reason for these differences may be due to beta-
lactam antagonism, perhaps through penicillin-binding
protein substrate competition [21,22]. However, a recent
study found a lack of antagonism between oxacillin and
vancomycin against MSSA [23].
The differences in mortality among patients who
received vancomycin compared to those who received naf-
cillin or cefazolin may also be explained by pharmacody-
namic differences among these agents, particularly with
respect to their interactions with innate host defense
molecules. Not only are nafcillin or cefazolin more potent
bactericidal agents in vitro compared to vancomycin, but
they also act synergistically with innate host defense catio-
nic antimicrobial peptides such as platelet microbicidal
proteins (PMPs) in killing S. aureus [24].
The recent clinical practice guidelines by the Infectious
Disease Society of America for the treatment of MRSA
stated that vancomycin “is clearly inferior to beta-lactams
for MSSA bacteremia and infective endocarditis” and cited
five studies to support this statement [25]. Two of the
cited studies assessed the use of vancomycin among intra-
venous drug users with endocarditis [26,27]. The three
other cited studies compared outcomes among patients
with S. aureus bacteremia who received vancomycin and
those who received nafcillin or cefazolin [7-9]. Chang et al.
found that nafcillin was superior to vancomycin in pre-
venting recurrence of S. aureus bacteremia but that study
was not designed to assess mortality and did not assess
the impact of switching from vancomycin to nafcillin [7].
In contrast, Stryjewski et al. evaluated a cohort of hemo-
dialysis-dependent patients with MSSA bacteremia, in
which all patients initially received vancomycin. They
found that treatment failure was more common among
patients who continued on vancomycin compared to those
who were switched to a first-generation cephalosporin
(adjusted Odds Ratio: 3.5; 95% CI: 1.2, 13.5). In that study,
treatment failure was defined as death or recurrent infec-
tion, but it was not sufficiently powered to assess mortality
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sus beta-lactams among MSSA bacteremia patients
admitted to two South Korean hospitals. They found that
receipt of vancomycin was associated with increased mor-
tality (adjusted OR: 3.3; 95% CI: 1.2, 9.5). However, less
than 10% of the patients in that study received vancomy-
cin. Thus their results may not be generalizable to other
populations in which a higher proportion of S. aureus bac-
teremic patients receive vancomycin [9]. Additionally,
three more studies compared vancomycin to beta-lactam
antibiotics among patients with endocarditis or pneumo-
nia and found that those who received vancomycin had
worse patient outcomes [28-30].
None of the prior studies assessed the benefits of switch-
ing from vancomycin to nafcillin or cefazolin in a general
patient population, as we have shown here. This finding
identifies a potential target for interventions designed to
improve antibiotic prescribing and infectious disease out-
comes. A clinical alert or reminder to switch to nafcillin or
cefazolin in non-allergic patients with MSSA bacteremia
would be expected to improve clinical outcomes with
minimal costs.
This current study is a subset of a larger cohort of all
UMMC patient admissions with S. aureus bacteremia,
including both MRSA and MSSA. Similar to our current
findings, in the larger cohort we found that appropriate
definitive antibiotic therapy was protective against mortal-
ity; however, appropriate empiric antibiotic therapy was
not protective against mortality [19]. Thus, a short time to
receipt of antibiotics may not be as important as eventual
receipt of optimal antibiotics.
Our study had several limitations. The results could be
affected by residual confounding because patients who
received nafcillin or cefazolin were healthier compared to
those who received vancomycin. However, through our
propensity scores we controlled for many factors that may
affect health such as severity of illness, aggregate comor-
bidity, endocarditis and receipt of other anti-staphylococ-
cal antibiotics. In addition, our multivariable analysis
suggested that switching to nafcillin or cefazolin was asso-
ciated with a 69% reduction in risk of 30-day mortality. It
would be unlikely that residual confounding, beyond the
numerous factors that we already controlled for, could
explain away such a profound protective effect. The
receipt of other anti-staphylococcal antibiotics may also
have led to residual confounding in this study. Yet,
patients who received nafcillin or cefazolin were signifi-
cantly less likely to receive other antibiotics compared to
patients who received vancomycin. Additionally, there was
no significant difference in mortality between patients who
received only vancomycin versus vancomycin plus another
antibiotic other than nafcillin or cefazolin (data not
shown). Thus, the benefits of additional antibiotics would
bias our results toward the null.
Our study was limited by its retrospective observational
design. A randomized control study design would be pre-
ferred to study this association, but some clinicians may
consider it unethical to randomly assign patients with
MSSA to vancomycin given these findings. Due to the ret-
rospective design of this study, we were not able to evalu-
ate the duration or drug levels of antibiotic treatment.
Thus under-dosing may be unrecognized, especially
among hemodialysis patients. Additionally, only 19% of
the patients with S. aureus bacteremia had an echocardio-
graphic evaluation and only 60% of cases classified as
endocarditis had an echocardiography. Thus, our measure-
ment of endocarditis may be less accurate than measure-
ments done prospectively.
This study suggests that patients with MSSA bacteremia
should receive nafcillin or cefazolin as soon as the patho-
gen is definitively identified by culture since there was a
69% lower risk of death in those patients who were
switched from vancomycin. Thus, these results imply that
clinicians should not continue vancomycin for dosing
scheduling convenience, as any benefits from simplified
dosing schedules would be greatly outweighed by the sur-
vival benefits of switching to nafcillin or cefazolin. An
unmeasured potential implication of this study is that the
choice to switch patients from vancomycin to nafcillin or
cefazolin may decrease vancomycin selection pressure,
thus delaying the emergence of decreased susceptibility to
vancomycin.
Conclusions
In summary, receipt of nafcillin or cefazolin was indepen-
dently associated with decreased mortality compared to
vancomycin in MSSA bacteremia therapy. This benefit per-
sists even if receipt is delayed until definitive culture results
are available. Choice of empiric antibiotic therapy must
weigh MRSA coverage against potentially superior antibio-
tics. Nafcillin or cefazolin should be considered as the treat-
ment of choice for definitive therapy for MSSA bacteremia.
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